The potential role of unrelated donor cord blood transplantation (UD-CBT) in adults is not well established. We report the results of UD-CBT in nine adult patients with chronic myeloid leukemia (CML). The median age was 27 years (range, 19-41 years), and the median weight was 62 kg (range, 45-78 kg). At transplant, six patients were in chronic phase (five in first, and one in second), two in blast crisis, and one in accelerated phase. Eight had received intensive chemotherapy, and three had undergone autologous peripheral blood hematopoietic stem cell transplantation. Four had received interferon with no cytogenetic response, and only three underwent UD-CBT within 1 year of diagnosis. After serological typing for class I antigens, and high-resolution DNA typing for DRB1, the degree of HLA match between patients and cord blood (CB) units was 4/6 in six cases and 5/6 in three cases. The median number of nucleated cells infused was 1.7 × 10 7 /kg (range, 1.2 to 4.9 × 10 7 /kg), and was above 2 × 10 7 /kg in only two cases. All patients received thiotepa, busulfan, cyclophosphamide and anti-thymocyte globulin as conditioning; cyclosporine and prednisone for graft-versushost disease (GVHD) prophylaxis; and G-CSF from day +7 until engraftment. All seven evaluable cases engrafted. The median time to reach an absolute neutrophil count у0.5 × 10 9 /l and у1 × 10 9 /l was 22 days (range, 19-52 days) and 28 days (range, 23-64 days), respectively. In the four patients evaluable for platelet recovery time to levels of у20 × 10 9 platelets/l, у50 × 10 9 platelets/l, and у100 × 10 9 platelets/l, these ranged from 50 to 128 days, 60 to 139 days, and 105 to 167 days, respectively. Three patients developed acute GVHD above grade II, and three of the five patients at risk developed extensive chronic GVHD. Four patients, all transplanted in chronic phase, remain alive in mol- 
together with several cases from among three heterogeneous series of patients with different diseases, two from registries including mainly pediatric cases, 13, 16 and one of adults from a single institution. 21 This deficit has been due mainly to grave concerns about the possibility of engraftment failure after UD-CBT in adults. Thus, the potential role of UD-CBT in adults with CML remains unclear.
The major aim of this study was to evaluate the results of UD-CBT in a pilot series of nine consecutive, homogeneously treated, adult patients with CML, who lacked a closely HLA-matched family donor or histocompatible MUD. All seven evaluable patients engrafted successfully. Four patients transplanted in chronic phase remain alive, in molecular remission, with full donor chimerism, more than 18 to 42 months after transplantation.
Patients and methods

Patients and eligibility criteria
Between May 1997 and July 2000, nine consecutive patients with Philadelphia chromosome (Ph)-positive CML underwent UD-CBT at our institution. Patients were eligible for enrollment if they met all the following criteria: (1) diagnosis of Ph-positive CML, (2) lack of a suitably histocompatible or closely HLA-matched related donor, (3) failure, after a 4 month search through International Bone Marrow Donor registries to identify a potential HLA-identical MUD, and (4) provision of signed informed consent. The local Institutional Review Board approved the information given to patients and the provision of informed consent. In most cases, an autologous back-up of bone marrow or mobilized peripheral blood hematopoietic progenitors was available for a potential engraftment failure. The main characteristics of the patients, previous therapies for CML before UD-CBT, the phase of the disease at transplant, the time elapsed from diagnosis to transplant, and the duration of the BM-MUD search are presented in Table 1 . 442  CP2  25  Female  55  Hydroxyurea, DAV, IFN, APBSCT  102  Positive  443  CP1  19  Female  63  Hydroxyurea, DAV, IFN, APBSCT  63  Negative  546  CP1  30  Female  57  Hydroxyurea, ICE  9  Positive  550  CP1  33  Female  62  Hydroxurea, ICE  19  Positive  569  CP1  27  Female  78  Hydroxyurea  6  Positive  582  CP1  27  Female  55  Hydroxyurea, ICE  19 Positive 574  BC  22  Male  73  Hydroxyurea, IDA/ARA-C  8  Positive  638  BC  41  Female  45  Hydroxyurea, ICE, IFN, APBSCT  125  Positive  668  AP  39  Male  72  Hydroxyurea ICE, IFN  25 Positive UPN = unique patient number; CMV = cytomegalovirus; CP1 = first chronic phase; CP2 = second chronic phase; AP = accelerated phase; BC = blast crisis; DAV = daunorubicin, cytarabine, etoposide; ICE = idarubicin, cytarabine, etoposide; IFN = interferon ␣; APBSCT = autologous peripheral blood hematopoietic stem cell transplantation.
Patients transplanted in advanced disease
Selection of a CB unit
All formal searches were conducted by the Spanish Registry of Bone Marrow Donors (Registro Español de Donantes de Médula Osea; REDMO). The following criteria for the UD-CB units were mandatory: (1) Ͼ1 × 10 7 nucleated cells/kg recipient body weight in the cryopreserved CB unit, and (2) at least four HLA antigens in common with the potential recipient. For this purpose, HLA class I antigens (A and B) were identified by serological or low-resolution DNA typing, and class II antigens (DRB1) were identified by high-resolution DNA typing. After a preliminary search, those CB units that fulfilled the criteria specified above were scored first on the basis of degree of HLA match, and then on cell dose. When several units were available for a patient, we selected the one that best matched the patient's HLA haplotype, and which contained the highest number of nucleated cells (NC). When possible, mismatches within the same cross-reacting group of HLA antigens were preferred to major incompatibilities. In choosing among units with the same number of HLA disparities with the patient, no preference was given to mismatches at class I or class II major histocompatibility complex antigens. In those cases with more than one unit with the same degree of HLA mismatch and a similar number of NC, high-resolution DNA typing of class I antigens (HLA-A, -B and -C) and class II antigens (HLA-DRB1, -DQB1 and -DPB1) was performed, to find the unit with the best match. Confirmatory class I and class II HLA testing of the patient and CB units were performed in all instances. All transplanted CB units tested negative for human immunodeficiency virus, hepatitis B and C viruses, and human T cell lymphotropic virus type I. None of the units, nor the mothers of the donors, were positive for IgM antibody to cytomegalovirus (CMV).
HLA typing of patients and donors
All patients and CB units were HLA typed in our laboratory (DP), at least for confirmatory purposes. HLA class I serological typing was performed by a standard complement-dependent microlymphocytotoxicity technique. 22 HLA-A, -B, -C, -DRB, -DQA1 and -DQB1 low-or high-resolution genotyping was performed by polymerase chain reaction, with sequence-specific primers (SSP-PCR), 23 using Dynal (Oslo, Norway) commercial reagents, according to the manufacturer's instructions. HLA-DPB1 high-resolution genotyping was performed by PCR and reverse-hybridization with sequence-specific oligonucleotide probes (SSO-PCR), 24 using the INNO-LiPA DPB kit (Innogenetics, Ghent, Belgium), according to the manufacturer's instructions. All PCR reactions were carried out in a GeneAmp PCR System 9600 (Perkin Elmer, Norwalk, CT, USA).
Definition of HLA mismatching
For each donor-recipient pair, a 'major antigen mismatch' was defined as that HLA allele of the recipient that was not shared by the donor, on the basis of serology or lowresolution DNA techniques. A 'minor antigen mismatch' was defined as an HLA allele of the recipient that was not shared by the donor, using high-resolution DNA techniques, but which had the same HLA serological specificity, using serology or low-resolution DNA techniques.
Transplantation procedure
Cryopreserved CB units were transported to the Centro de Trasfusión de la Comunidad Valenciana in a shipping container cooled by liquid nitrogen in vapor phase, and stored in liquid nitrogen until use. The CB unit canister was left in the gas vapor phase for 5-10 min before proceeding. The canister was carefully opened, avoiding damage to the frozen blood bag, and the identifying information was verified. Thawing of CB units was performed by Rubinstein et al's method, 25 with minor modifications. The CB unit was submerged in a 37°C water bath. It was placed immediately into a transfer bag, and mixed with an equal volume of thawing solution, containing 10% dextran 40 and 5% human albumin. After equilibrating for 5 min, the transfer bag was placed in a centrifuge carrier, and centrifuged at 400 g, for 10 min at 10°C. Once the supernatant was removed, the cell pellet was resuspended in 50 ml thawing solution. Samples for cell counts, CD34
+ cell analysis, viability, clonogenic assays, and microbiology were drawn directly from the bag before infusion. Cells counts were performed with an autoanalyzer Sysmex K800 (Toa Medical Electronics, Kobe, Japan). CD34 + cells were quantified by flow cytometry, using a FACScalibur cytometer with Procount software (Becton Dickinson, San José, CA, USA). Cell viability was assessed with ethidium bromide and acridine orange staining. Clonogenic assays were performed using a commercially prepared complete methylcellulose medium (Methocult GF H4434; Stem Cell Technologies, Vancouver, Canada), supporting growth of CFU-GM, BFU-E and CFU-GEMM.
Preparative regimen and GVHD prophylaxis
The conditioning regimen consisted of thiotepa (5 mg/kg per day) on days −9 and −8; busulfan (1 mg/kg every 6 h) on days −7, −6 and −5; cyclophosphamide (60 mg/kg per Bone Marrow Transplantation day) on days −4 and −3; and horse anti-thymocyte globulin (ATG, Lymphoglobuline; Merieux, Lyon, France) (15 mg/kg per day) on days −5, −4, −3 and −2. To avoid ATG-associated infusion syndrome, patients concomitantly received paracetamol, chlorpheniramine and methylprednisolone. G-CSF (5 g/kg per day, subcutaneously) was given from day +7 until neutrophil engraftment. As GVHD prophylaxis, all patients received cyclosporine (3 mg/kg per day intravenously, followed by 3-5 mg/kg every 12 h by mouth when oral intake was possible, and tapered by 10% per week after day +180) and prednisone (0.5 mg/kg on days +7 to +14; 1 mg/kg on days +14 to +28, with gradual tapering until day +180). Patients developing acute GVHD received high-dose methylprednisolone as an initial therapy, followed by ATG in refractory cases.
Supportive care
Patients were kept in reverse isolation, under highefficiency particulate air filtration. Ciprofloxacin, cotrimoxazole and fluconazole were given as antibacterial, antiPneumocystis carinii and antifungal prophylaxes, respectively. The use of empirical or adapted intravenous antibiotics and liposomal amphotericin B, and the transfusion policy used, were those usually employed when handling neutropenic patients. All transfused products were irradiated and leukocyte-depleted. As CMV prophylaxis, intravenous acyclovir (400 mg/m 2 every 12 h) was administered from day −5 until engraftment, followed by prophylactic intravenous ganciclovir (5 mg/kg per day) 3 to 5 days per week, from engraftment until day +100. Patients were monitored for CMV antigenemia by leukocyte expression of the CMV-p65 antigen twice weekly until day +120, and once weekly from days +120 to +180. Patients who developed CMV antigenemia received pre-emptive ganciclovir (5 mg/kg every 12 h) for 14 days, or until 7 days after the clearance of CMV antigen from the blood, whichever occurred later, followed by a dose of 5 mg/kg per day for 5 days/week, over 2 weeks. Patients who developed a second episode of CMV antigenemia before day +120 received ganciclovir (as above), or foscarnet. Patients who had more than one episode of CMV antigenemia received CMV prophylaxis with oral ganciclovir (3 g/day) or aciclovir (800 mg five times per day) until day +180. Non-specific intravenous immunoglobulin was administered to each patient, at a dose of 500 mg/kg weekly, to day +100, and then monthly during the first year after transplant.
Chimerism studies PCR-VNTR: DNA was extracted from donor and recipient peripheral blood (PB) cells, or bone marrow cells, before UD-CBT, using a salting-out procedure. 26 For PCR amplification, we used specific primers designed to flank the repeated units of the following human minisatellite regions: D1S80, 33.6, YNZ-22, APO-B and DXS52. [27] [28] [29] HLA PCR-typing of antigen mismatches: During followup, HLA-A, -B, -C, -DRB, -DQA1 and -DQB1 low-or high-resolution genotyping was performed, using SSP-PCR, whereas HLA-DPB1 high-resolution genotyping was performed by SSO-PCR (see above).
Fluorescence in situ hybridization (FISH):
For oppositesex transplants, an estimate of the proportion of donor and recipient cells was made using the CEP X SpectrumOrange/Y SpectrumGreen DNA Probe kit (Vysis, Downers Grove, IL, USA). Hybridization was performed according to the protocols provided by the manufacturer. Whenever possible, at least 500 interphase nuclei in BM and/or PB specimens were evaluated.
Studies of residual disease
Detection of BCR/ABL transcripts by RT-PCR: RNA was isolated from mononuclear cells by the guanidinium-thiocyanate-phenol-chloroform procedure of Chomczynski and Sacchi. 30 Reverse transcription was performed on 1 g total RNA in a 25 l final reaction volume, with 200 U MMuLV-reverse transcriptase (Promega, Madison, WI, USA), using random hexamer primers. The reaction was incubated at 42°C for 1 h, and the reverse transcriptase was inactivated at 65°C for 10 min. The BCR/ABL amplification was performed taking 5 l cDNA in a 25 l final volume, following the nested PCR method of Cross et al. 31 The amplification products were separated on a 2% agarose minigel, stained with ethidium bromide, and visualized under UV transillumination. The b3a2 breakpoint yields a 456 bp product, whereas the b2a2 breakpoint gives a 385 bp product. To ensure the quality of the cDNA, the ABL gene was amplified in a single PCR, following the method of Cross et al. 31 
Detection of BCR/ABL rearrangements by FISH:
The presence of BCR/ABL rearrangements was also evaluated by FISH. The LSI BCR/ABL Extra Signal Dual Color DNA Probe (Vysis) was used for that purpose. A sample was considered positive when there were more than 2% positive cells.
Definitions and statistical analysis
Patients surviving more than 30 days after transplantation were considered evaluable for engraftment. Myeloid engraftment was defined as an absolute neutrophil count (ANC) of 0.5 × 10 9 /l or greater, on 3 consecutive days, and platelet engraftment as a platelet count of 50 × 10 9 /l or higher, without transfusion support, for 7 consecutive days. Time to myeloid or platelet engraftment was defined as the time required to reach the first day of engraftment of the relevant lineage. Secondary graft failure was defined as the loss of an engrafted transplant. Acute and chronic GVHD were defined and graded according to standard criteria. All statistical analyses were carried out with software from the BMDP library.
Results
Patient characteristics
Nine patients with CML received transplants between May 1997 and July 2000. This figure represents all potential candidates for whom a suitable cord blood unit was found during the study period. Characteristics of the patients are given in Table 1 . There were seven women and two men, and the median age at transplant was 27 years (range, 19-41 years). The median weight of the patients was 62 kg (range, 45-78 kg). The disease was in chronic phase in six patients (five in first, and one in second chronic phase), in blast crisis in two, and in accelerated phase in one patient. Seven patients had previously received idarubicin or daunorubicin, etoposide and cytarabine, followed by G-CSF for mobilization and harvest of hematopoietic progenitors from peripheral blood, as part of an ongoing protocol for autologous peripheral blood hematopoietic stem cell transplantation (APBSCT). One patient in blast crisis had received daunorubicin and cytarabine, in an unsuccessful attempt to revert the disease to chronic phase. Three patients (two transplanted in chronic phase, and one in blast crisis) had undergone a previous APBSCT 24 months, 33 months and 34 months before UD-CBT, respectively. Four patients had previously received interferon, without achieving a cytogenetic response. The median time from diagnosis to UD-CBT was 19 months (range, 6-125 months), and only three patients were transplanted within 1 year after CML diagnosis (one of them in blast crisis). Eight patients had a high titer of IgG anti-CMV antibody.
CB unit characteristics and degree of HLA mismatch
Four CB units were supplied by the Barcelona Cord Blood Bank, three by the Placental Blood Program at the New York Blood Center, and two by the Milano Cord Blood Bank.
By means of serological typing for class I antigens, and low-resolution DNA typing for class II HLA alleles, five CB units were matched for 4/6 HLA antigens, three for 5/6, and one showed a complete match. After typing for DRB1 by high-resolution DNA analysis, the HLA match was 4/6 in six cases, and 5/6 in three cases. In seven cases, HLA-A, and -B antigens were typed by high-resolution DNA techniques. In two of them, one additional mismatch was present. Table 2 shows the degree of HLA match for the different patients, assessed by low-or high-resolution techniques.
The median number of total nucleated cells (TNC) infused was 1.7 × /kg). There was a major ABO blood group mismatch in three cases, and a minor mismatch in one. Table 3 Mismatches are shown in bold-type letters UPN = unique patient number; NA = not available. depicts the cell dose, ABO blood group match, donor/recipient gender match, and the time elapsed between storage of CB unit and transplantation in each case. The median time from the start of the search for a CB unit to transplant was 166 days (range, 103-362 days).
Engraftment
Data concerning hematopoietic engraftment are shown in Table 4 . Two patients died on days +10 and +25, and were considered unevaluable for engraftment. In the remaining seven patients, the median time to reach an ANC Bone Marrow Transplantation Ͼ0.1 × 10 9 /l, Ͼ0.5 × 10 9 /l, and Ͼ1 × 10 9 /l was 14 days (range, 14-30 days), 22 days (range, 19-52 days), and 28 days (range, 23-64 days), respectively. These seven patients showed full donor chimerism at a median time of 14 days (range, 14-36 days) after transplant. The patient who had the slowest engraftment had been transplanted in a blast phase refractory to AML chemotherapy, and had a persistent massive splenomegaly. As full donor chimerism and an ANC Ͼ0.1 × 10 9 /l had been present for 3 weeks, he underwent splenectomy on day +74. The ANC returned to normal immediately after surgery. Five patients died between 10 and 154 days after transplant, without platelet recovery. In the remaining four patients, the periods till platelet counts reached Ͼ20 × 10 9 platelets/l, Ͼ50 × 10 9 platelets/l, and Ͼ100 × 10 9 platelets/l ranged from 50 to 128 days, 60 to 139 days, and 105 to 167 days, respectively. Secondary graft failure has not been observed in any patient so far.
Acute and chronic GVHD
All patients developed acute GVHD. The clinical grading of acute GVHD was grade I in three cases, grade II in three cases, and grade IV in three cases (Table 5) . Skin involvement was observed in all cases (stage ++ in five, stage +++ in two and stage ++++ in two), intestinal involve- ment in three cases (stage + in one and ++++ in two), and liver involvement in four cases (stage + in two, stage +++ in one and stage ++++ in one). The clinical diagnosis of GVHD was histopathologically confirmed by skin biopsy in three cases, and at autopsy in two cases. The median time to the development of acute GVHD was 9 days (range, 7-14 days). Acute GVHD was responsive to high-dose methylprednisolone in six patients, refractory in two with grade IV acute GVHD, and unevaluable in the remaining one. Neither of the two patients with steroid-refractory acute GVHD responded to salvage therapy for GVHD. All five patients at risk developed chronic GVHD. Chronic GVHD was limited in two cases, and extensive in three. Chronic GVHD was responsive to prednisone and cyclos-porine, except in one patient in whom chronic GVHD had progressed from refractory acute GVHD. The median time to the development of chronic GVHD ranged from 100 to 277 days. It is noteworthy that none of the patients with chronic GVHD had hepatic involvement, whereas three had pulmonary involvement, which is suggestive of bronchiolitis obliterans, of mild to moderate degree.
Outcome
The two patients transplanted in blast phase died 30 and 154 days after transplant, due to massive hemorrhage and refractory GVHD, respectively. Interestingly, both patients had myeloid engraftment, and showed full donor chimerism at the time of death. At that point, one of them was BCR/ABL negative by RT-PCR, and the other, who was only evaluated by FISH, showed no BCR/ABL rearrangement. The patient transplanted in accelerated phase died from infection and multiorgan failure on day +10. Four of the six patients transplanted in chronic phase (three in first, and one in second chronic phase) remain alive and diseasefree, with normal blood counts and full donor chimerism, and are BCR/ABL negative (by RT-PCR), more than 18, 19, 24 and 42 months after transplantation. The Karnofsky activity score in these patients ranges from 90% to 100%. The surviving patient with the longest follow-up had been autografted previously. The two remaining patients who were transplanted in first chronic phase died 25 and 44 days after UD-CBT, the former from Acinetobacter spp. sepsis and central nervous system toxicity, and the latter from GVHD, hemorrhage, and multiorgan failure. The patient outcomes are presented in Table 5 .
Discussion
This series of UD-CBT in adults with high-risk CML, the largest group from a single institution to be published until now, demonstrates short-and long-term hematopoietic engraftment, and the prospects for cure in patients transplanted in the chronic phase of the disease. Since 1988, when the first successful CB transplantation was performed in a child with Fanconi's anemia, 32 this source of hematopoietic progenitors has been increasingly employed, mainly in pediatric patients, in a wide variety of hematological and congenital disorders. UD-CBT has several potential advantages over BMT from a marrow unrelated donor. These include a lower risk of transmissible infectious diseases, an absence of risk to the donor, a lack of donor attrition, and rapid availability. 15 However, the lower number of hematopoietic stem cells in CB, compared to bone marrow, together with preliminary data showing the importance of cell dose to the outcome of CBT, 13, 16 have been of major concern and, in fact, have limited the use of UD-CBT in adults. 15 Until now, information about the results of UD-CBT has only been available through registries, 13, 16, 21 in small series from single institutions, 12, 14, 33 or as anecdotal case reports. 19, 20, [34] [35] [36] [37] In all instances, the populations of patients and the conditioning regimens in these series have been heterogeneous. Furthermore, with just two exceptions, 21 ,38 all these series have
Bone Marrow Transplantation pooled both child and adult cases. As a consequence, it is almost impossible, at present, to estimate the role of UD-CBT in adults with a particular disorder. The present series included only adult patients with CML, who received the same conditioning, and were managed uniformly in terms of prophylaxis and treatment of GVHD, as well as with respect to anti-infection policy. In our series, the cell dose infused was very similar to that reported for adults by the New York Placental Blood Program, 16 Eurocord, 13, 38 and Duke University, 21 and is clearly lower than that reported for children. 13, 16 An almost universal myeloid engraftment in adults undergoing UD-CBT has also been reported, as an abstract, by the team at Duke University. 21, 39 In their early report of 22 consecutive UD-CBT in adult recipients with different disorders, all 17 evaluable patients engrafted. 39 In a more recent report from this institution, 21 including 38 transplants in adults, two patients experienced autologous recovery, and six died from infection between days 18 and 89 after transplantation, with no evidence of engraftment. The more extensive, but also more heterogeneous, UD-CBT series of 108 adults reported by Eurocord, had a myeloid engraftment rate of 81% at 60 days. 38 On the other hand, we have observed a somewhat shorter time to myeloid engraftment than expected for adults undergoing UD-CBT. 13, 16, 21, 38 It is conceivable that the high intensity of conditioning, and the use of ATG to further decrease the immune response in the recipient, could have facilitated engraftment in our patients. In agreement with previous studies in both children and adults, [13] [14] [15] [16] platelet engraftment was delayed after UD-CBT. Nonetheless, it should be noted that all four cases with sufficient follow-up demonstrated a complete and sustained recovery of platelet counts to normal levels. Full donor chimerism was observed very shortly after transplant, before day +21 in all but one case, and this chimerism status is persisting in all cases.
Previous reports from registries, including mainly children, suggest that, in spite of a higher degree of HLA mismatch, the risk of acute and chronic GVHD after UD-CBT is lower than after MUD-BMT. 13, 16 A recent non-randomized comparative study of UD-CBT and MUD-BMT in children with acute leukemia, by Eurocord, has shown a lower risk of GVHD in UD-CBT. Preliminary data in adults point in the same direction. In spite of the fact that 35 of 38 patients in the Duke University series were mismatched in one to three HLA-antigens, only 13 patients developed grade II to IV acute GVHD. 21 Among 108 adults with hematological malignancies reported to Eurocord, of whom 102 had at least one HLA mismatch (one in 38, two in 52 and three in 13), the probability of developing grade III-IV acute GVHD was 30%, and chronic GVHD occurred in 15 of 58 patients at risk. 38 In the present series, all patients at risk experienced some degree of acute (grade IV in three) and chronic GVHD. Although higher than in other reports, this incidence of GVHD is less than would be expected in adults receiving bone marrow from mismatched unrelated donors. GVHD was responsive to initial therapy in most patients. Interestingly, the clinical pattern of chronic GVHD seems somewhat different to that usually seen after MUD-BMT. None of the patients had hepatic involvement, whereas three patients had pulmonary symp-toms, suggestive of bronchiolitis obliterans of moderate degree. In a previous report on UD-CBT, 16 pulmonary disease contributed to death in 26% of cases. Our preliminary data suggest that isolated lung involvement in GVHD could explain, in part, the high incidence of pulmonary complications in these patients.
The lower incidence of GVHD after UD-CBT, compared with MUD-BMT, has raised the suspicion that UD-CBT could present a higher risk of relapse. Recent data comparing UD-CBT and MUD-BMT in children with acute leukemia, suggest this is not the case. 18 Similar data have emerged from a recently published joint report by IBMTR and Eurocord, comparing CBT and BMT from HLA-identical siblings among children with leukemia. 17 In our short experience, none of the patients has relapsed, and all remain in molecular remission at last follow-up. Interestingly, both patients transplanted in blast phase attained cytogenetic remission after transplantation, and one of them was in molecular remission at the time of death from refractory GVHD.
At present, the long-term outcomes for adult patients undergoing CB transplantation cannot be properly estimated, owing to small numbers and heterogeneous patient populations. In reports including children and adults, the cell dose infused per kilogram, measured as TNC per kilogram 13, 16 or CFU-GM infused per kilogram, 40 has emerged as a major prognostic factor for survival. This is not surprising, as this variable not only reflects the cell dose content of the CB units but, indirectly, other recognized prognostic factors for outcome after allogeneic stem cell transplantation, such as age 10, 11 and weight. 10 Disease status, another important predictive variable of survival after transplantation, might also be related to the cell dose infused. Physicians caring for patients could more frequently select a unit with a lower cellular content than desired, in cases of advanced disease or high risk of relapse, where the clinical condition of the patient precludes waiting for a better cord blood unit. Furthermore, recent data from Eurocord show that, in adults, survival at 1 year after UD-CBT is quite similar, irrespective of the cell dose infused, when more than 1 × 10 7 NC/kg are infused (unpublished observations). The status of the disease at transplant has also emerged as a strong indicator of outcome after UD-CBT. 16, 38, 41 In the present series of CML patients undergoing UD-CBT, four of six patients transplanted in chronic phase remain alive more than 1 to 3 years after transplantation. In contrast, all three patients transplanted in more advanced phases died.
UD-CBT is a new kind of therapy for hematological malignancies. Increasing experience in the use of MUD-BMT has been shown to greatly increase the success of the procedure. The disease-free survival rate in CML patients undergoing MUD-BMT has increased considerably in recent years. 10, 11 The same will probably hold true for UD-CBT. In fact, recent unpublished data from Eurocord show a significantly higher survival in UD-CBT performed after 1998, probably reflecting a better policy for the selection of cord blood units for transplant.
Our data, in agreement with previous reports, show that UD-CBT, in spite of the low cellular dose infused, is capable of promoting sustained hematopoietic engraftment in adult recipients. These data also suggest that UD-CBT can result in long-term survival in a substantial proportion of patients with CML, transplanted in chronic phase. These preliminary results, like other available data, suggest that indications for UD-CBT in adults should be reviewed. A comparative study of UD-CBT and MUD-BMT in adults with CML should be undertaken.
